2017 SECIM P&F Projects

In 2017, SECIM awarded pilot & feasibility project funds to the following researchers:

  • Dr. Elizabeth Barton, University of Florida
    “Defining metabolic shifts in mouse muscles lacking IGF-I production”
  • Dr. Kathryn Blake, Nemours Children’s Hospital
    “Using Metabolomics and Lipidomics Analysis to Explore Metabolites and Pathways Associated Increased Airway Hyperresponsiveness in Patients with Asthma who are Identified by Race (African American) and Genotype (ADRB2 Arg16/Arg)”
  • Dr. Mariola Edelmann, University of Florida
    “Profiling of extracellular and exosome-contained metabolites in Salmonella infection”
  • Dr. Kelly Ethun, Emory University
    “Milk Metabolomics and Infant Neurodevelopment in the Rhesus Macaque Model”
  • Dr. Michelle Gumz, University of Florida
    “Urinary Metabolite Profile of Non-Dipping Hypertension”
  • Dr. Jayoung Kim, University of California, Los Angeles
    “Integrated Metabolomics in Aggressive Bladder Cancer”
  • Dr. Jennifer Kwong, Emory University
    “Metabolomic Analysis of Mitochondrial Energy Dysfunction in the Heart”
  • Dr. George Kyriazis, Sanford Burnham Prebys Medical Discovery Institute
    “Skeletal Muscle Sweet Taste Receptors and Nutrient Utilization”
  • Dr. Joshua Patterson, University of Florida
    “Linking Metabolome and Phenotype in an Endangered Coral Cultured for Reef Restoration”
  • Dr. Rody Wellington Jr, University of Florida
    “Metabolomic profiling of gingival crevicular fluid (GCF) in the presence of dentin resorption”
  • Dr. Joseph Ryan, University of Florida
    “Using comparative metabolomics to understand growth and salt tolerance in mangroves”
  • Dr. Irwin Van Meir, Emory University
    “Define mechanism of action and metabolic vulnerabilities induced by novel anti-cancer agent 64B”
  • Dr. Rui Xiao, University of Florida
    “Metabolic profiling of a ketogenic diet-triggered anti-aging effects in C. elegans”
  • Dr. Yi Xu, Texas A&M University
    “Determine metabolomics signatures important for the ability of Streptococus gallolyticus to promote colon cancer cell proliferation”